A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by William J. French (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- William J. French (ucla)
Adjunct Professor, Medicine. Authored (or co-authored) 98 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
- ID
- NCT05803421
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 2620 study participants
- Last Updated